BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 35180322)

  • 21. Effects of Wuzhi Capsule on Whole-Blood Tacrolimus Concentration Levels: A Systematic Review and Meta-Analysis.
    Zhang C; Ren X; Liu Y; Huang L; Feng Y; Zhang X
    Ther Drug Monit; 2024 Feb; 46(1):33-41. PubMed ID: 38150711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Evaluation of the Efficacy and Safety of Co-Administration of Wuzhi Capsule and Tacrolimus in Adult Chinese Patients with Myasthenia Gravis.
    Peng Y; Jiang F; Zhou R; Jin W; Li Y; Duan W; Xu L; Yang H
    Neuropsychiatr Dis Treat; 2021; 17():2281-2289. PubMed ID: 34285488
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of CYP3A5 and ABCB1 Gene Polymorphisms on Tacrolimus Blood Concentration in Renal Transplant Recipients.
    Yildirim E; Şahin G; Kaltuş Z; Çolak E
    Clin Lab; 2019 Nov; 65(11):. PubMed ID: 31710427
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Wuzhi Capsule Dosage Affects Tacrolimus Elimination in Adult Kidney Transplant Recipients, as Determined by a Population Pharmacokinetics Analysis.
    Chen L; Yang Y; Wang X; Wang C; Lin W; Jiao Z; Wang Z
    Pharmgenomics Pers Med; 2021; 14():1093-1106. PubMed ID: 34511980
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Examination of the Impact of CYP3A4/5 on Drug-Drug Interaction between Schizandrol A/Schizandrol B and Tacrolimus (FK-506): A Physiologically Based Pharmacokinetic Modeling Approach.
    He Q; Bu F; Wang Q; Li M; Lin J; Tang Z; Mak WY; Zhuang X; Zhu X; Lin HS; Xiang X
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35562875
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of long-term co-administration of Wuzhi tablet (Schisandra sphenanthera extract) and prednisone on the pharmacokinetics of tacrolimus.
    Qin XL; Yu T; Li LJ; Wang Y; Gu HM; Wang YT; Huang M; Bi HC
    Phytomedicine; 2013 Feb; 20(3-4):375-9. PubMed ID: 23267661
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.
    Tada H; Tsuchiya N; Satoh S; Kagaya H; Li Z; Sato K; Miura M; Suzuki T; Kato T; Habuchi T
    Transplant Proc; 2005 May; 37(4):1730-2. PubMed ID: 15919447
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Investigation of the Impact of
    He Q; Bu F; Zhang H; Wang Q; Tang Z; Yuan J; Lin HS; Xiang X
    Pharmaceuticals (Basel); 2021 Feb; 14(3):. PubMed ID: 33673653
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prediction of Drug-Drug Interaction between Tacrolimus and Principal Ingredients of Wuzhi Capsule in Chinese Healthy Volunteers Using Physiologically-Based Pharmacokinetic Modelling.
    Zhang H; Bu F; Li L; Jiao Z; Ma G; Cai W; Zhuang X; Lin HS; Shin JG; Xiang X
    Basic Clin Pharmacol Toxicol; 2018 Mar; 122(3):331-340. PubMed ID: 28945011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.
    Tsuchiya N; Satoh S; Tada H; Li Z; Ohyama C; Sato K; Suzuki T; Habuchi T; Kato T
    Transplantation; 2004 Oct; 78(8):1182-7. PubMed ID: 15502717
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation.
    Goto M; Masuda S; Kiuchi T; Ogura Y; Oike F; Okuda M; Tanaka K; Inui K
    Pharmacogenetics; 2004 Jul; 14(7):471-8. PubMed ID: 15226679
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of CYP3A5 polymorphism on the pharmacokinetics of a once-daily modified-release tacrolimus formulation and acute kidney injury in hematopoietic stem cell transplantation.
    Yamashita T; Fujishima N; Miura M; Niioka T; Abumiya M; Shinohara Y; Ubukawa K; Nara M; Fujishima M; Kameoka Y; Tagawa H; Hirokawa M; Takahashi N
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):111-8. PubMed ID: 27217047
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients.
    Quteineh L; Verstuyft C; Furlan V; Durrbach A; Letierce A; Ferlicot S; Taburet AM; Charpentier B; Becquemont L
    Basic Clin Pharmacol Toxicol; 2008 Dec; 103(6):546-52. PubMed ID: 19067682
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Wuzhi capsule regulates chloroacetaldehyde pharmacokinetics behaviour and alleviates high-dose cyclophosphamide-induced nephrotoxicity and neurotoxicity in rats.
    Chen L; Xiong X; Hou X; Wei H; Zhai J; Xia T; Gong X; Gao S; Feng G; Tao X; Zhang F; Chen W
    Basic Clin Pharmacol Toxicol; 2019 Aug; 125(2):142-151. PubMed ID: 30793490
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of CYP3A5*3 polymorphism on pharmacokinetic drug interaction between tacrolimus and amlodipine.
    Zuo XC; Zhou YN; Zhang BK; Yang GP; Cheng ZN; Yuan H; Ouyang DS; Liu SK; Barrett JS; Li PJ; Liu Z; Tan HY; Guo R; Zhou LY; Xie YL; Li ZJ; Li J; Wang CJ; Wang JL
    Drug Metab Pharmacokinet; 2013; 28(5):398-405. PubMed ID: 23438946
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Melding Pharmacogenomic Effect of
    Prasad N; Jaiswal A; Behera MR; Agarwal V; Kushwaha R; Bhadauria D; Kaul A; Gupta A
    Kidney Int Rep; 2020 Jan; 5(1):28-38. PubMed ID: 31922058
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Personalized tacrolimus doses determined by CYP3A5 genotype for induction and maintenance phases of kidney transplantation.
    Vannaprasaht S; Reungjui S; Supanya D; Sirivongs D; Pongskul C; Avihingsanon Y; Tassaneeyakul W
    Clin Ther; 2013 Nov; 35(11):1762-9. PubMed ID: 24120259
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.
    Zhang X; Liu ZH; Zheng JM; Chen ZH; Tang Z; Chen JS; Li LS
    Clin Transplant; 2005 Oct; 19(5):638-43. PubMed ID: 16146556
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of cyclosporin A in rats.
    Xue XP; Qin XL; Xu C; Zhong GP; Wang Y; Huang M; Bi HC
    Phytother Res; 2013 Aug; 27(8):1255-9. PubMed ID: 22996305
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of CYP3A5 and MDR1 polymorphisms on tacrolimus dosage requirements and trough concentrations in pediatric renal transplant recipients.
    Shilbayeh S; Zmeili R; Almardini RI
    Saudi J Kidney Dis Transpl; 2013 Nov; 24(6):1125-36. PubMed ID: 24231473
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.